NICE published an impact report on diagnostic pathology

11

Jun 2021

In May 2021, NICE published an impact report on diagnostic pathology. NICE diagnostics assessment program produces guidance that evaluates innovative diagnostic technologies. NICE has a special adoption team that supports the uptake of new technologies recommended by NICE. They also support the NHS Accelerated Access Collaborative (AAC), which brings together industry, government, regulators, patients, and the NHS to remove barriers and accelerate the introduction of new treatments and diagnostics.

The report provides uptake data of the following NICE-recommended pathology diagnostics:

  • High-sensitivity troponin tests (AAC rapid uptake product):
    • 86% of eligible people had access to high-sensitivity troponin tests;
  • Placental growth factor (PIGF)-based tests for suspected pre-eclampsia (AAC rapid uptake product):
    • Only one hospital had access to PlGF-based tests in 2018/19 compared with 60 who had access to the tests in 2019/20;
  • Faecal immunochemical test (FIT) for colorectal cancer:
    • In June 2019, FIT became the primary test used in the bowel cancer screening program for people aged 60 to 74;
    • The uptake of the screening test increased from 56% in 2015/16 to 66% in 2019/20;
  • Faecal calprotectin tests for inflammatory diseases of the bowel:
    • After implementing the test, Yorkshire and Humber Academic Health Science Network successfully rolled out the pathway to 15 clinical commissioning groups (CCGs) by 2020. It was estimated that using the pathway CCGs would save approximately £220,000 a year by preventing unnecessary and expensive colonoscopies;
  • Prenatal testing for fetal RHD genotype:
    • University Hospitals Bristol NHS Foundation Trust implemented this test in 2017 and reduced anti-D immunoglobulin use by 29%;
    • Taunton and Somerset NHS Foundation Trust reported that adoption of prenatal testing resulted in a 40% reduction in anti-D immunoglobulin use;
  • Natriuretic peptide testing - B‑type natriuretic peptide (BNP) or N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP) for heart failure:
    • There is a lack of uptake data;
  • Follicle-stimulating hormone (FSH) test for diagnosing menopause:
    • As an example, York Teaching Hospital NHS Foundation Trust implemented strategies to reduce inappropriate FSH requests for women aged over 45 recommended by NICE. FSH requests in women over 45 years had decreased by 34%, leading to a saving of around £7,500 in one year.

Furthermore, NICE provides its plans for improving pathology data and uptake of NICE-recommended diagnostics:

  • Make pathways consistent across providers, in line with NICE guidance;
  • Improve data collection to identify gaps in uptake.

See full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

22

Jun 2021

In late May 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0177 and 0074 with changes to be implemented not later than August 01, 2021. Five new procedure codes related to diagnostic imaging, ENT, breast reconstruction, and gynecology, and nine new diagnostic codes were introduced.

Read more

21

Jun 2021

On June 16, 2021, the Institute for Quality and Efficiency in Health Care (IQWiG) has opened the submission period for proposals for topics of the health technology assessment (HTA) reports to be developed in 2022.

Read more

18

Jun 2021

In May 2021, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (ex-situ machine perfusion for extracorporeal preservation of lungs for transplant, transvaginal laser therapy for stress urinary incontinence and for urogenital atrophy, electrohydraulic lithotripsy for difficult-to-treat bile duct stones, and permanent His-bundle pacemaker for heart failure), one new Medical Technologies Guidance (UroLift for benign prostatic hyperplasia), and two new Medtech Innovation Briefings (Axonics sacral neuromodulation system for faecal incontinence and KODEX-EPD for cardiac imaging during ablation of arrhythmias). Also, three clinical guidelines and two Medical Technologies Guidance were updated.

Read more

17

Jun 2021

In late May 2021, the Treatment Council (Behandlingsråd), a new framework for assessing treatments and health technologies in Denmark, started accepting applications for the assessment of health technologies.

Read more

16

Jun 2021

The Health Sciences Institute in Aragon (IACS) systematically evaluates healthcare technologies and facilitates the promotion of research, effective innovation, and decision-making in health services through knowledge management. Currently, the IACS is working on assessments of efficacy, effectiveness, and safety of intraoperative radiation therapy in breast cancer, determination of preeclampsia biomarkers SFlt-1 and PlGF, treatment of congenital ventricular septal defect by cardiac catheterization, and others.

Read more